Recce Pharmaceuticals

Recce Pharmaceuticals Net Tangible Assets

The Net Tangible Assets of Recce Pharmaceuticals (RCE.AX) as of Nov 22, 2026 is -16.72 M AUD. In the previous year, Net Tangible Assets was -3.05 M AUD — a change of 447.93% (lower).

Net Tangible Assets

-16.72 MAUD

YoY

447.93%

Last updated:

Net Tangible Assets of Recce Pharmaceuticals is 2026 -16.72 M AUD. Net Tangible Assets of Recce Pharmaceuticals was 2025 -3.05 M AUD. It decreases by 447.93% lower compared to the previous year.

The Recce Pharmaceuticals Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2019
-405,604.00 AUD
Jan 1, 2020
2.31 M AUD
Jan 1, 2021
20.50 M AUD
Jan 1, 2022
10.06 M AUD
Jan 1, 2023
-2.59 M AUD
Jan 1, 2024
-9.52 M AUD
Jan 1, 2025
-3.05 M AUD
Jan 1, 2026
-16.72 M AUD
The Recce Pharmaceuticals Net Tangible Assets history
YEARNet Tangible AssetsYoY
-16.72 MAUD+447.93%
-3.05 MAUD-67.95%
-9.52 MAUD+267.88%
-2.59 MAUD-125.73%
10.06 MAUD-50.93%
20.50 MAUD+786.62%
2.31 MAUD-670.16%
-405,604.00AUD-158.37%
694,915.00AUD+17.75%
590,144.00AUD-83.20%
3.51 MAUD-25.46%
4.71 MAUD-8,487.60%
-56,189.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recce Pharmaceuticals Stock analysis

What does Recce Pharmaceuticals do? Recce Pharmaceuticals Ltd. develops pharmaceutical drugs targeting germ-killing therapies, focusing on anti-infective solutions. The company’s pipeline includes RECCE 327, an intravenous and topical therapy for serious bacterial infections including superbugs, RECCE 435 as an oral treatment for bacterial infections, and RECCE 529 for viral infections. All compounds are 100% water soluble across all pH levels in liquid form, leveraging multi-layered mechanisms to combat bacterial and viral mutations. The company operates through research and development, with no additional product lines or services mentioned. Recce Pharmaceuticals Ltd. generates revenue primarily through the development and potential commercialization of its anti-infective drugs. The target market includes healthcare providers and institutions treating serious infections, particularly those dealing with antibiotic-resistant bacteria and viral pathogens. The company’s focus on broad-spectrum synthetic polymer anti-infectives positions it for partnerships with pharmaceutical distributors and healthcare systems seeking novel treatments for life-threatening infections. The business model relies on the progression of its drug pipeline from research to clinical trials and eventual market entry. RECCE 327, RECCE 435, and RECCE 529 are the only products described, with no mention of licensing agreements, partnerships, or additional revenue streams beyond drug development and sales. The company’s financial success depends on the successful advancement of these compounds through regulatory approval processes. Recce Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recce Pharmaceuticals stock

Net Tangible Assets of Recce Pharmaceuticals is -16.72 M AUD in 2026.

Net Tangible Assets of Recce Pharmaceuticals changed from -3.05 M AUD to -16.72 M AUD, representing a 447.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Recce Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Recce Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Recce Pharmaceuticals

All Key Metrics — Recce Pharmaceuticals